FDA Approves Updated Label For Eli Lilly and Company (LLY)'s Amyvid To Support Alzheimer's Diagnosis

Eli Lilly and Company (NYSE:LLY) is among the Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy. On June 25, the company announced that the FDA had approved a label update for Amyvid to support the diagnosis of Alzheimer’s disease.

The florbetapir F 18 injection is used for brain imaging of patients with cognitive impairment who are being tested for Alzheimer’s. Eli Lilly and Company (NYSE:LLY) said the new label changes will include revised guidelines to estimate plaque density and provide a new indication for patient selection.

The updated label will also allow the quantification of amyloid plaque levels in conjunction with visual understanding. Moreover, the clinical studies section of the label will acknowledge that amyloid beta positron emission tomography (PET) scans had aided in assessing plaque reduction in some trials of amyloid-targeting therapies.

Mark Mintun, M.D., group vice president, Neuroscience Research & Development, at Eli Lilly and Company (NYSE:LLY), stated the following on the development:

“Nearly 80% of Americans would prefer to know if they have an Alzheimer’s diagnosis before their memory and thinking symptoms disrupt daily life, highlighting the importance of advanced diagnostic tools like amyloid PET and blood biomarker testing. The modernization of Amyvid’s label is a significant step in advancing Alzheimer’s care, enabling physicians to help patients make informed decisions, being evaluated for or to aid in the selection of patients who are indicated for amyloid-targeting therapy.”

Eli Lilly and Company (NYSE:LLY) is a medicine company that has pioneered life-changing discoveries for the last 150 years, helping tens of millions of patients across the globe.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Big Name Stocks to Buy Now and Buffett Stock Portfolio: Top 10 Stock Picks for 2025.

Disclosure: None.